{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:34:07Z","timestamp":1740155647319,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T00:00:00Z","timestamp":1407196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1038\/nrneph.2014.132","type":"journal-article","created":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T08:11:00Z","timestamp":1407226260000},"page":"485-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Kidney volume\u2014a crystal ball for ADPKD prognosis?"],"prefix":"10.1038","volume":"10","author":[{"given":"Emilie","family":"Cornec-Le Gall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Le Meur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,5]]},"reference":[{"key":"BFnrneph2014132_CR1","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham, J. J.  et al. Volume progression in polycystic kidney disease. N. Engl. J. Med. 354, 2122\u20132130 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2014132_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman, A. B.  et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 7, 479\u2013486 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2014132_CR3","doi-asserted-by":"publisher","unstructured":"Irazabal, M. V.  et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J. Am. Soc. Nephrol. \n                    http:\/\/dx.doi.org\/10.1681\/ASN.2013101138\n                    \n                  .","DOI":"10.1681\/ASN.2013101138"},{"key":"BFnrneph2014132_CR4","unstructured":"Mayo Foundation for Medical Education and Research. Classification of Typical ADPKD Calculator \n                    [online]\n                    \n                  ."},{"key":"BFnrneph2014132_CR5","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz, G.  et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830\u2013840 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2014132_CR6","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra, A. L.  et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820\u2013829 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2014132_CR7","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E.  et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407\u20132418 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2014132_CR8","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","volume":"382","author":"A Caroli","year":"2013","unstructured":"Caroli, A.  et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 382, 1485\u20131495 (2013).","journal-title":"Lancet"},{"key":"BFnrneph2014132_CR9","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1681\/ASN.2012070650","volume":"24","author":"E Cornec-Le Gall","year":"2013","unstructured":"Cornec-Le Gall, E.  et al. Type of PKD1 mutation influences renal outcome in ADPKD. J. Am. Soc. Nephrol. 24, 1006\u20131013 (2013).","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.132","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:43:34Z","timestamp":1684471414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2014.132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,5]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["BFnrneph2014132"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2014.132","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"type":"print","value":"1759-5061"},{"type":"electronic","value":"1759-507X"}],"subject":[],"published":{"date-parts":[[2014,8,5]]},"assertion":[{"value":"5 August 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.C. L.G. declares that she has received travel grants from Otsuka and Roche. Y.L.M. declares that he has received research funding, honoraria for speaking and travel grants from Astellas, Chiesi, Novartis, Otsuka, Roche and Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}